Published in Breast Cancer Res on December 20, 2001
Reduction in bone relapse and improved survival with oral clodronate for adjuvant treatment of operable breast cancer [ISRCTN83688026]. Breast Cancer Res (2006) 1.71
Combination effect of oncolytic adenovirotherapy and TRAIL gene therapy in syngeneic murine breast cancer models. Cancer Gene Ther (2006) 0.92
Targeting the alphavbeta3 integrin for small-animal PET/CT of osteolytic bone metastases. J Nucl Med (2009) 0.91
Alendronate decreases orthotopic PC-3 prostate tumor growth and metastasis to prostate-draining lymph nodes in nude mice. BMC Cancer (2008) 0.90
Animal Models of Bone Metastasis. Vet Pathol (2015) 0.84
Nitrogen-containing bisphosphonates inhibit cell cycle progression in human melanoma cells. Br J Cancer (2004) 0.82
Adjuvant bisphosphonate treatment for breast cancer: Where are we heading and can the pre-clinical literature help us get there? J Bone Oncol (2012) 0.81
The role of the bone microenvironment in skeletal metastasis. J Bone Oncol (2012) 0.79
Does estrogen play a role in response to adjuvant bone-targeted therapies? J Bone Oncol (2013) 0.76
The distribution of secondary growths in cancer of the breast. 1889. Cancer Metastasis Rev (1989) 13.15
Reduction in new metastases in breast cancer with adjuvant clodronate treatment. N Engl J Med (1998) 6.09
Efficacy of pamidronate in reducing skeletal complications in patients with breast cancer and lytic bone metastases. Protocol 19 Aredia Breast Cancer Study Group. N Engl J Med (1996) 5.87
TGF-beta signaling blockade inhibits PTHrP secretion by breast cancer cells and bone metastases development. J Clin Invest (1999) 5.30
Structure-activity relationships for inhibition of farnesyl diphosphate synthase in vitro and inhibition of bone resorption in vivo by nitrogen-containing bisphosphonates. J Pharmacol Exp Ther (2001) 3.59
Cellular and molecular mechanisms of action of bisphosphonates. Cancer (2000) 3.57
Evidence for a causal role of parathyroid hormone-related protein in the pathogenesis of human breast cancer-mediated osteolysis. J Clin Invest (1996) 3.44
Bisphosphonates induce apoptosis in human myeloma cell lines: a novel anti-tumour activity. Br J Haematol (1997) 2.14
Bisphosphonates induce apoptosis in human breast cancer cell lines. Br J Cancer (2000) 2.12
Bisphosphonate risedronate reduces metastatic human breast cancer burden in bone in nude mice. Cancer Res (1995) 1.97
Actions of bisphosphonate on bone metastasis in animal models of breast carcinoma. Cancer (2000) 1.78
Adjuvant clodronate treatment does not reduce the frequency of skeletal metastases in node-positive breast cancer patients: 5-year results of a randomized controlled trial. J Clin Oncol (2001) 1.76
Development of bisphosphonates. Breast Cancer Res (2001) 1.63
Osteolytic bone metastasis in breast cancer. Breast Cancer Res Treat (1994) 1.61
The bisphosphonate ibandronate promotes apoptosis in MDA-MB-231 human breast cancer cells in bone metastases. Cancer Res (2001) 1.57
Bisphosphonates inhibit the adhesion of breast cancer cells to bone matrices in vitro. J Clin Invest (1996) 1.44
Bisphosphonates inhibit prostate and breast carcinoma cell adhesion to unmineralized and mineralized bone extracellular matrices. Cancer Res (1997) 1.39
The bisphosphonate incadronate (YM175) causes apoptosis of human myeloma cells in vitro by inhibiting the mevalonate pathway. Cancer Res (1998) 1.39
Molecular mechanisms of action of bisphosphonates. Bone (1999) 1.33
Palliative pamidronate treatment in patients with bone metastases from breast cancer. J Clin Oncol (1993) 1.32
In vitro cytoreductive effects on multiple myeloma cells induced by bisphosphonates. Leukemia (1998) 1.27
Characteristics of clodronate-induced apoptosis in osteoclasts and macrophages. Mol Pharmacol (1996) 1.19
Preclinical studies with zoledronic acid and other bisphosphonates: impact on the bone microenvironment. Semin Oncol (2001) 1.05
Zoledronate is a potent inhibitor of myeloma cell growth and secretion of IL-6 and MMP-1 by the tumoral environment. J Bone Miner Res (1999) 1.04
Anti-tumor potential of bisphosphonates. Med Klin (Munich) (2000) 1.01
Direct effects of bisphosphonates on breast cancer cells. Breast Cancer Res (2001) 0.98
Effect of the bisphosphonate risedronate on bone metastases in a rat mammary adenocarcinoma model system. J Bone Miner Res (1994) 0.94
Influence of clodronate on breast cancer cells in vitro. Eur J Med Res (1998) 0.90
Effect of a newly developed bisphosphonate, YH529, on osteolytic bone metastases in nude mice. Int J Cancer (1998) 0.90
Prophylactic treatment of skeletal metastases, tumor-induced osteolysis, and hypercalcemia in rats with the bisphosphonate Cl2MBP. Cancer (1993) 0.82
Treatment with ibandronate preserves bone in experimental tumour-induced bone loss. J Bone Joint Surg Br (2000) 0.78
Increased growth rate and tumor burden of spontaneously metastatic Walker 256 cancer cells in the skeleton of bisphosphonate-treated rats. Cancer Res (1993) 0.77
A multigenic program mediating breast cancer metastasis to bone. Cancer Cell (2003) 16.86
Cancer to bone: a fatal attraction. Nat Rev Cancer (2011) 4.08
Molecular biology of bone metastasis. Mol Cancer Ther (2007) 2.71
A causal role for endothelin-1 in the pathogenesis of osteoblastic bone metastases. Proc Natl Acad Sci U S A (2003) 2.23
Differential stem- and progenitor-cell trafficking by prostaglandin E2. Nature (2013) 1.99
Transforming growth factor-beta stimulates parathyroid hormone-related protein and osteolytic metastases via Smad and mitogen-activated protein kinase signaling pathways. J Biol Chem (2002) 1.95
Stable overexpression of Smad7 in human melanoma cells impairs bone metastasis. Cancer Res (2007) 1.89
Breast cancer metastasis to bone: mechanisms of osteolysis and implications for therapy. J Mammary Gland Biol Neoplasia (2005) 1.75
Hypoxia and TGF-beta drive breast cancer bone metastases through parallel signaling pathways in tumor cells and the bone microenvironment. PLoS One (2009) 1.72
Osteoporosis in men with prostate carcinoma receiving androgen-deprivation therapy: recommendations for diagnosis and therapies. Cancer (2004) 1.69
GLI2-mediated melanoma invasion and metastasis. J Natl Cancer Inst (2010) 1.68
TGF-beta-RI kinase inhibitor SD-208 reduces the development and progression of melanoma bone metastases. Cancer Res (2010) 1.68
Guide to bone health and disease in cystic fibrosis. J Clin Endocrinol Metab (2004) 1.67
Tumor-derived interleukin-8 stimulates osteolysis independent of the receptor activator of nuclear factor-kappaB ligand pathway. Cancer Res (2005) 1.65
Pharmacologic inhibition of the TGF-beta type I receptor kinase has anabolic and anti-catabolic effects on bone. PLoS One (2008) 1.60
The calcium-sensing receptor is required for normal calcium homeostasis independent of parathyroid hormone. J Clin Invest (2003) 1.53
TGF-β/SMAD/GLI2 signaling axis in cancer progression and metastasis. Cancer Res (2011) 1.49
Dickkopf homolog 1 mediates endothelin-1-stimulated new bone formation. Mol Endocrinol (2006) 1.44
Calcium release channel RyR2 regulates insulin release and glucose homeostasis. J Clin Invest (2015) 1.38
Metastasis and bone loss: advancing treatment and prevention. Cancer Treat Rev (2010) 1.32
The critical role of the bone microenvironment in cancer metastases. Mol Cell Endocrinol (2009) 1.31
TGF-β in cancer and bone: implications for treatment of bone metastases. Bone (2010) 1.20
Molecular mechanisms and treatment of bone metastasis. Expert Rev Mol Med (2008) 1.12
Guanosine nucleotides inhibit different syndromes of PTHrP excess caused by human cancers in vivo. J Clin Invest (2002) 1.12
RANKL/RANK/MMP-1 molecular triad contributes to the metastatic phenotype of breast and prostate cancer cells in vitro. PLoS One (2013) 1.08
The role of TGF-β in bone metastasis: novel therapeutic perspectives. Bonekey Rep (2012) 1.06
TGF-β in the Bone Microenvironment: Role in Breast Cancer Metastases. Cancer Microenviron (2011) 1.05
Assessing new bone formation in neonatal calvarial organ cultures. Methods Mol Biol (2008) 1.03
Advancing treatment for metastatic bone cancer: consensus recommendations from the Second Cambridge Conference. Clin Cancer Res (2008) 1.00
The human Cyr61 gene is a transcriptional target of transforming growth factor beta in cancer cells. Cancer Lett (2006) 0.98
Anti-placental growth factor reduces bone metastasis by blocking tumor cell engraftment and osteoclast differentiation. Cancer Res (2010) 0.97
Mechanisms of osteoblastic metastases: role of endothelin-1. Clin Orthop Relat Res (2003) 0.95
Protein kinase Calpha regulates Ets1 transcriptional activity in invasive breast cancer cells. Int J Oncol (2003) 0.94
Molecular mechanisms of bone metastasis and therapeutic implications. Clin Orthop Relat Res (2003) 0.92
Halofuginone inhibits the establishment and progression of melanoma bone metastases. Cancer Res (2012) 0.91
Adrenomedullin is a cross-talk molecule that regulates tumor and mast cell function during human carcinogenesis. Am J Pathol (2006) 0.90
Skeletal metastases: decreasing tumor burden by targeting the bone microenvironment. J Cell Biochem (2007) 0.90
c-Fms signaling mediates neurofibromatosis Type-1 osteoclast gain-in-functions. PLoS One (2012) 0.90
Cancer therapy associated bone loss: implications for hip fractures in mid-life women with breast cancer. Clin Cancer Res (2011) 0.88
Calcium release channel RyR2 regulates insulin release and glucose homeostasis. J Clin Invest (2015) 0.87
Decreased autocrine EGFR signaling in metastatic breast cancer cells inhibits tumor growth in bone and mammary fat pad. PLoS One (2012) 0.87
Estrogenic side effects of androgen deprivation therapy. Rev Urol (2007) 0.87
Curcuminoids block TGF-β signaling in human breast cancer cells and limit osteolysis in a murine model of breast cancer bone metastasis. J Nat Prod (2012) 0.85
New insights into the role of T cells in the vicious cycle of bone metastases. Curr Opin Rheumatol (2006) 0.84
The haploinsufficient hematopoietic microenvironment is critical to the pathological fracture repair in murine models of neurofibromatosis type 1. PLoS One (2011) 0.84
Tgf-Beta pathway as a therapeutic target in bone metastases. Curr Pharm Des (2010) 0.84
Cancer treatment-related bone disease. Crit Rev Eukaryot Gene Expr (2009) 0.84
Mechanisms and treatment for bone metastases. Clin Adv Hematol Oncol (2004) 0.82
Cancer-associated osteoclast differentiation takes a good look in the miR(NA)ror. Cancer Cell (2013) 0.82
Regulation of postnatal trabecular bone formation by the osteoblast endothelin A receptor. J Bone Miner Res (2011) 0.81
Hyperactive transforming growth factor-β1 signaling potentiates skeletal defects in a neurofibromatosis type 1 mouse model. J Bone Miner Res (2013) 0.81
Heparin-like polysaccharides reduce osteolytic bone destruction and tumor growth in a mouse model of breast cancer bone metastasis. Mol Cancer Res (2012) 0.80
Therapeutic strategies to target TGF-β in the treatment of bone metastases. Curr Pharm Biotechnol (2011) 0.80
Advances in treating metastatic bone cancer: summary statement for the First Cambridge Conference. Clin Cancer Res (2006) 0.80
Cancer-associated bone disease. Curr Osteoporos Rep (2007) 0.79
Local effects of malignancy on bone. Curr Opin Endocrinol Diabetes Obes (2007) 0.78
Overexpression of parathyroid hormone-related protein causes hypercalcemia but not bone metastases in a murine model of mammary tumorigenesis. J Bone Miner Res (2002) 0.78
Agents targeting prostate cancer bone metastasis. Anticancer Agents Med Chem (2009) 0.77
Spontaneous bone metastases in a preclinical orthotopic model of invasive lobular carcinoma; the effect of pharmacological targeting TGFβ receptor I kinase. J Pathol (2015) 0.77
Breaking new ground to build bone. Proc Natl Acad Sci U S A (2007) 0.77
Drug insight: the use of bisphosphonates for the prevention and treatment of osteoporosis in men. Nat Clin Pract Urol (2007) 0.76
BMP7: a new bone metastases prevention? Am J Pathol (2007) 0.76
The reaction of bone to tumor growth from human breast cancer cells in a rat spine single metastasis model. Spine (Phila Pa 1976) (2011) 0.76
Does prostate-specific antigen contribute to bone metastases? Clin Cancer Res (2006) 0.75
Corrigendum: Oxygen-sensing PHDs regulate bone homeostasis through the modulation of osteoprotegerin. Genes Dev (2015) 0.75